Jefferies Financial Group Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences (NASDAQ:ROIV) had its price target lifted by equities research analysts at Jefferies Financial Group from $42.00 to $52.00 in a research report issued on Tuesday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 24.63% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, August 25th. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. HC Wainwright reissued a “buy” rating and issued a $41.00 target price on shares of Roivant Sciences in a research report on Friday, August 28th. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.14.

Roivant Sciences Trading Up 19.5%

Shares of NASDAQ:ROIV traded up $6.79 during trading on Tuesday, hitting $41.73. 10,572,013 shares of the company’s stock traded hands, compared to its average volume of 6,163,936. The company has a 50-day moving average price of $35.30 and a 200-day moving average price of $31.26. Roivant Sciences has a 52 week low of $12.90 and a 52 week high of $42.09. The company has a market cap of $30.14 billion, a price-to-earnings ratio of -78.56 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, analysts predict that Roivant Sciences will post -2 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Gold sold 800,000 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the completion of the sale, the director directly owned 13,701,546 shares in the company, valued at approximately $473,388,414.30. This represents a 5.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,055,913 shares of company stock valued at $107,261,258. Insiders own 8.80% of the company’s stock.

Institutional Trading of Roivant Sciences

Several institutional investors have recently added to or reduced their stakes in ROIV. SBI Securities Co. Ltd. raised its holdings in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in Roivant Sciences in the fourth quarter valued at $47,000. Parallel Advisors LLC lifted its stake in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after purchasing an additional 520 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its stake in Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.